Abionyx Pharma Valuation Multiples

Abionyx Pharma Overview

About Abionyx Pharma

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Founded

2005

HQ

Employees

5

Website

abionyx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5M

EBITDA: ($14M)

EV

$139M

Valuation Multiples

Multiples.vc

Start free trial

Abionyx Pharma Financials

Abionyx Pharma reported last 12-month revenue of $5M and negative EBITDA of ($14M).

In the same LTM period, Abionyx Pharma generated ($14M) in EBITDA losses and had net loss of ($10M).

Abionyx Pharma P&L

In the most recent fiscal year, Abionyx Pharma reported revenue of $5M and EBITDA of ($5M).

Abionyx Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Abionyx Pharma Stock Performance

Abionyx Pharma has current market cap of $138M, and enterprise value of $139M.

Abionyx Pharma's stock price is $3.91.

Abionyx Pharma Valuation Multiples

Abionyx Pharma trades at 28.6x EV/Revenue multiple, and (9.8x) EV/EBITDA.

Abionyx Pharma Financial Valuation Multiples

As of March 23, 2026, Abionyx Pharma has market cap of $138M and EV of $139M.

Equity research analysts estimate Abionyx Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Abionyx Pharma has a P/E ratio of (13.8x).

Abionyx Pharma Margins & Growth Rates

Abionyx Pharma's revenue in the last 12 month grew by 65%.

Abionyx Pharma's revenue per employee in the last FY averaged $1.0M.

Abionyx Pharma's rule of 40 is (226%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Abionyx Pharma's rule of X is (129%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Abionyx Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Abionyx Pharma M&A Activity

Abionyx Pharma acquired XXX companies to date.

Last acquisition by Abionyx Pharma was on XXXXXXXX, XXXXX. Abionyx Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Abionyx Pharma Investment Activity

Abionyx Pharma invested in XXX companies to date.

Abionyx Pharma made its latest investment on XXXXXXXX, XXXXX. Abionyx Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).